In a groundbreaking initiative poised to redefine our understanding of cancer biology, researchers at Scripps Research have embarked on an ambitious project to decode a hidden layer of cancer control embedded within chemical modifications of RNA molecules. This research, propelled by a substantial grant from the National Cancer Institute’s RNA Modifications Driving Oncogenesis (RNAMoDO) program, aims to unravel how these subtle molecular tags influence tumor progression and cancer cell adaptation. The project promises to chart new frontiers in cancer research by elucidating mechanisms that have remained elusive despite extensive genetic studies.
Traditionally, cancer has been viewed primarily through the lens of genomic mutations—faulty DNA instructions that lead to unchecked cellular proliferation. However, mounting evidence suggests that this genomic narrative is incomplete without considering epitranscriptomics—the chemical modification of RNA molecules that regulate gene expression post-transcriptionally. RNA modifications, especially methylation on tRNAs and ribosomal RNAs, play a pivotal role in fine-tuning protein synthesis. Disruptions in these modifications may reprogram cancer cells’ protein production machinery, enabling malignancy and therapeutic resistance.
The helm of this pioneering endeavor is Professor James Williamson, the Cecil H. and Ida M. Green Chair of Chemistry at Scripps Research. Collaborating with him are esteemed scientists Gary Siuzdak, also from Scripps, specializing in metabolomics, and Rachel Green, a Bloomberg Distinguished Professor at Johns Hopkins University School of Medicine. Over the course of the next five years, their integrated approach will scrutinize the dynamic landscape of RNA modifications in the context of cancer and nutrient availability, with funding nearing $5 million contingent on ongoing approvals.
Central to their focus is the phenomenon of methylation influenced by methionine, an essential amino acid found abundantly in protein-rich diets. Methionine serves as the primary methyl donor in various cellular processes, including the methylation of RNA molecules. Both ribosomes and transfer RNAs, critical players in protein synthesis, bear numerous methyl groups that shape their function. The availability of methionine thus critically regulates these epitranscriptomic marks, with direct implications for how cancer cells modulate their proteome in response to environmental cues.
Recent studies have underscored the potential of dietary methionine restriction as a strategy to curb cancer growth, yet the molecular underpinnings of this phenomenon remain poorly defined. This research aims to bridge that gap by dissecting how methionine scarcity remodels the chemical landscape of RNA within cancer cells. Using advanced mass spectrometry, Williamson’s laboratory will precisely map alterations in methylation and other modifications on ribosomal RNAs and tRNAs, providing a molecular atlas of response to nutrient stress.
Complementing this, Siuzdak’s metabolomics expertise will illuminate shifts in the intracellular availability of methionine and related metabolites, revealing how fluctuations in nutrient pools interface with epitranscriptomic remodeling. This integrative analysis promises unprecedented insights into the metabolic-epitranscriptomic crosstalk that governs cancer cell survival and proliferation under nutrient-limiting conditions.
To translate these molecular alterations into functional outcomes, Rachel Green’s team will employ ribosome profiling, an innovative method that captures snapshots of active translation across the cancer cell genome. By quantifying which mRNAs are preferentially translated and which are downregulated in response to altered RNA modifications, the researchers can connect molecular changes directly to shifts in protein synthesis—a critical determinant of cancer cell behavior.
Such mechanistic clarity is vital, as it could unveil novel therapeutic targets aimed at disrupting cancer’s adaptive translational program. Understanding how methionine-driven methylation patterns sculpt the proteomic landscape offers a tangible entry point for interventions. It could also rationalize and refine dietary methionine restriction protocols, enhancing their efficacy and applicability across diverse cancer types.
Beyond methylation, this initiative is poised to pioneer a broader exploration of RNA modifications—chemical tags that extend well beyond methyl groups and whose roles in oncogenesis remain largely uncharted. By establishing robust frameworks and methodological paradigms, the project sets a foundation for future studies to chart the complex epitranscriptomic networks in cancer.
The implications of this research extend beyond cancer, as RNA modifications have emerged as fundamental regulators of cellular physiology in health and disease. The ability to dynamically modulate protein synthesis through chemical tags on RNA offers a versatile regulatory layer with far-reaching biological significance.
This pioneering work is a testament to the power of interdisciplinary collaboration, blending chemistry, metabolomics, and molecular biology to tackle the intricate metabolic and molecular labyrinth of cancer. By focusing on the metabolic basis of epitranscriptomic changes, the researchers cast light on the profound ways in which nutrient signals influence cancer progression.
As cancer therapeutics evolve towards precision medicine, understanding the nuanced interplay between metabolism and gene expression at the RNA level will be crucial. This research paves the way for innovative therapeutic strategies that exploit cancer cells’ metabolic vulnerabilities, potentially leading to treatments with higher specificity and fewer side effects.
Funded under award number 1U01CA305256-01, this RNAMoDO program project reflects the cutting edge of cancer research, promising to illuminate the RNA modifications that drive oncogenesis and to open new avenues for intervention.
Through this comprehensive and multifaceted investigation, Scripps Research, alongside Johns Hopkins University, is set to redefine our grasp of cancer biology—shifting from a purely genetic perspective to one that embraces the dynamic and complex chemical alphabet written on RNA.
Subject of Research:
RNA modifications influencing cancer cell growth and methionine-dependent methylation processes
Article Title:
Scripps Research Leads Transformative Study on RNA Modifications and Nutrient-Driven Cancer Growth
News Publication Date:
Information not provided
Web References:
https://www.scripps.edu/faculty/williamson/
https://www.scripps.edu/faculty/siuzdak/
https://reporter.nih.gov/search/7T3nB_MDg0O7_j1rVJ3SXA/project-details/11226464
Image Credits:
Credit: Scripps Research
Keywords:
Cancer, RNA modifications, methylation, methionine restriction, ribosome profiling, metabolomics, translational control, epitranscriptomics, Scripps Research, National Cancer Institute, RNAMoDO program
Tags: cancer biology beyond genomic mutationscancer RNA modifications researchepitranscriptomics in oncologymolecular tags influencing cancer adaptationNational Cancer Institute RNAMoDO grantpost-transcriptional gene regulation in cancerprotein synthesis disruption in cancer cellsRNA methylation and tumor progressionRNA modifications driving oncogenesisRNA-based cancer growth controlScripps Research cancer studytherapeutic resistance mechanisms in tumors
